old dream| wrote an article

another| edit

On March 16, 2024, Ms. Wang Xuyu, General Manager of Sartorius China, and Ms. Ren Xueyun, Head of Bioprocess Marketing Department of Sartorius China, joined hands with industry leaders and Mr. Zhou Hang, Senior Vice President of WuXi Biotech, Mr. Chen Jianxin, CEO of Zhenge Biotech, and Mr. Xiao Xinzhou, Executive Director of Sherpa Biotechnology Operations, lit up the grand ceremony and injected new vitality into China's biotechnology field.

At the meeting, Ms. Wang Xuyu, General Manager of Sartorius China, introduced a historical node in the launch of this innovative process, and mentioned that after experiencing rapid development, China's biomedical industry is now about to move towards an efficient, technological and green new stage. And Sartorius hopes to integrate into this new transformation trend with his own innovative solutions.

Wang Xuyu, General Manager of Sedolis China

Ms. Ren Xueyun, head of the Bioprocess Marketing Department of Sartorius in China, shared the characteristics of the one-stop enhanced process launched by Sartorius this time, from full process coverage, cost reduction and efficiency improvement, time saving, flexible innovation, and low-carbon environmental protection. The advantages of innovation-enhanced processes are expounded in five aspects: five aspects: innovation and low-carbon and environmental protection. At the same time, it also announced a series of initiatives to be implemented in the future, aiming to promote the development of the biopharmaceutical industry in a more efficient innovation direction through this series of activities and cooperation with leading innovative partners in the industry.

Ren Xueyun, Head of Bioprocess Marketing Department in Sartorius China

- 01 -

A key node in biomedical process transformation

After biopharmaceuticals have ushered in a high-profile moment in China in the past few years, many macromolecular product companies still follow a "rough" operating model in the production process.

The reason is that in the past, under the zero-to-one dividend of China's innovative drugs, the focus of the entire industry was actually on the product, clinical and other directions. Everyone paid more attention to what kind of molecules, which mechanism, and how the data are... and process and production, as key aspects that will only be considered after commercialization, have not really entered the public's eye.

Zhou Hang, senior vice president of WuXi Biotech, said this at the scene:"** Over the past 20 years, the rapid development of the industry has promoted the continuous improvement of the level of biotechnology. Now it has reached an inflection point, and newer and better enhanced biotechnology is accelerating its implementation. This is another development direction in addition to relying on scale growth in the past. It is also a manifestation of the maturity of an industry's development. **”

Compared with traditional practices, innovative craftsmanship means technological, efficient and green, and this is also what the recent top-level design of "developing new productivity and promoting it through technological innovation" wants to promote.

Zhou Hang, Senior Vice President of WuXi Biotech

- 02 -

Empowering biopharmaceutical companies and empowering patients

The biopharmaceutical production process is complex. From cultivation to amplification, from filtration to purification, every link requires a large amount of equipment. These processes need to break the boundaries and develop in a more efficient direction.

This requires more reliable technologies and innovative methods to meet the requirements of new processes.

For pharmaceutical companies, the cost reduction and efficiency increase brought by process innovation are not only a long-term development trend, but also an improvement in the accessibility of medicines to patients under the current limited medical resources.

In recent years, new biotechnologies have emerged one after another, especially revolutionary new molecules and new mechanisms in the field of oncology. However, in addition to research and development, part of the high pricing of many drugs is the cost of the CMC link, especially CGT. Emerging immunotherapy represented.

This requires technological innovation in the process to bring lower production costs and more stable quality to innovative drugs.

Xiao Xinzhou, Executive Director of Biotechnology Operations, Sherpa

“By integrating Sartorius' advanced technologies into our manufacturing processes, Altriust ensures that it stays at the full fond of industry advancement and delivers life changing drugs to patients in needTogether we are shaping the landscape of Bio-pharmaceutical manufacturing bringing us closer to a world where health care solutions are effective and accessible to all”

Mr. Xiao Xinzhou, Executive Director of Sherpa Biotechnology Operations, said.

“They are very knowledgeable. Sartorius is world-class, just like Altruist. They would always work with us to find innovative solutions, enabling us to bring affordable drugs to patients worldwide.”

- 03 -

Work together to reshape the future of life sciences

The upstream process for the production of macromolecular drugs has two major directions. One is the scale of reactor reactors, and the other is the development of enhanced processes such as continuous production and continuous perfusion.

However, with the rapid development of genomics and the rapid increase in expression rates by orders of magnitude, process innovation in many downstream links has been slow for a long time due to regulatory and market awareness issues.

"The biopharmaceutical industry itself is an industry with very high requirements for quality and supervision. Innovation and breakthroughs must be based on rigorous development and verification, so ** This requires the joint efforts of pharmaceutical companies, suppliers, regulators and partners in the entire industry chain., to form a synergy to promote the development of enhanced processes. **" Zhou hang